Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Corcept Therapeutics (CORT) Gross Profit (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Gross Profit for 15 consecutive years, with $162.0 million as the latest value for Q1 2026.

  • For Q1 2026, Gross Profit rose 4.66% year-over-year to $162.0 million; the TTM value through Mar 2026 reached $755.6 million, up 12.0%, while the annual FY2025 figure was $748.4 million, 12.69% up from the prior year.
  • Gross Profit hit $162.0 million in Q1 2026 for Corcept Therapeutics, down from $199.6 million in the prior quarter.
  • Across five years, Gross Profit topped out at $203.0 million in Q3 2025 and bottomed at $92.4 million in Q1 2022.
  • Average Gross Profit over 5 years is $143.9 million, with a median of $144.3 million recorded in 2024.
  • Year-over-year, Gross Profit increased 4.21% in 2022 and then soared 47.33% in 2024.
  • Corcept Therapeutics' Gross Profit stood at $101.6 million in 2022, then soared by 31.46% to $133.5 million in 2023, then skyrocketed by 34.0% to $178.9 million in 2024, then grew by 11.54% to $199.6 million in 2025, then decreased by 18.82% to $162.0 million in 2026.
  • According to Business Quant data, Gross Profit over the past three periods came in at $162.0 million, $199.6 million, and $203.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.